WET AGE RELATED MACULAR DEGENERATION

This study follows 23 people who received a single dose of ADVM-022 gene therapy for wet age-related macular degeneration (AMD). Researchers are checking long-term safety and whether vision improvements last. Participants are observed over time without receiving additional treatm…

This phase 3 study tests a new drug, EYP-1901, against a standard treatment (aflibercept) for wet age-related macular degeneration, a leading cause of vision loss. About 400 adults with the condition will receive either EYP-1901 or aflibercept to see if the new drug can maintain …

This study tests two new medicines (tarcocimab tedromer and tabirafusp tedromer) against a standard treatment (aflibercept) for wet age-related macular degeneration, a leading cause of vision loss. About 675 people with untreated wet AMD will receive one of the three drugs as an …

This study tests whether people with wet age-related macular degeneration (AMD) can start with longer breaks between eye injections instead of the usual three monthly shots. It compares two drugs, aflibercept and brolucizumab, to see if they are equally effective at drying the re…

This phase 3 study tests EYP-1901, a new long-acting eye injection, against the standard treatment aflibercept in 400 people with wet age-related macular degeneration (AMD). The goal is to see if EYP-1901 can maintain or improve vision while reducing the number of injections need…

This study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…

This study evaluates a new system called AVIGA that uses eye-tracking to detect central vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the system's results with standard tests like eye scans and vision charts. The goal is to se…